Telekom Srbija Group Announces Platinum Sponsorship of EXPO 2027 Belgrade
Telekom Srbija to power EXPO 2027 and unveil dedicated pavilion showcasing its technology ecosystem BELGRADE, Serbia–(BUSINESS WIRE)–Telekom Srbija Group... Read more.
Axelspace Secures Japan Ministry of Defense Satellite Constellation Project
As an optical imagery provider, Axelspace has entered into a contract for the acquisition of image data TOKYO–(BUSINESS WIRE)–#axelspace–Axelspace... Read more.
G42 Joins Forces with Credo AI To Advance Responsible AI Adoption Across Global South
Together, G42 and Credo AI will operationalize Responsible AI across the Global South by turning governance principles into measurable impact NEW DELHI–(BUSINESS... Read more.
Sai Life Sciences to Recruit 700+ Professionals in FY27
HYDERABAD, India–(BUSINESS WIRE)–#AnalyticalDevelopment–Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE), one of India’s leading integrated... Read more.
Saba Capital Comments on the Proposed Combination of BlackRock Throgmorton Trust plc and BlackRock Smaller Companies Trust plc
Commends the Trusts’ Boards for Working Constructively with Shareholders and Proposing a Shareholder-Friendly Combination LONDON–(BUSINESS WIRE)–Saba... Read more.
SOLUM and EWQ Announce Strategic Partnership Expansion at EuroShop to Advance Integrated In-Store Digital Communication
DUESSELDORF, Germany–(BUSINESS WIRE)–#DigitalSignage—SOLUM (KOSPI: 248070), a global retail solutions provider, and EWQ, a leading retail infrastructure... Read more.
Kosmos Energy Announces Ratification of Ghana License Extensions by Parliament and Provides Trading Update
DALLAS–(BUSINESS WIRE)–Kosmos Energy (NYSE/LSE: KOS) (“Kosmos” or the “Company”) is pleased to confirm that the license extensions for the West... Read more.
FDA Approves Genentech’s Venclexta® Plus Acalabrutinib Combination Regimen for Previously Untreated Chronic Lymphocytic Leukemia
– First and only all-oral, fixed-duration regimen designed to provide CLL patients with the potential to experience time off treatment – – Approval expands... Read more.
FDA Accepts New Drug Application for Genentech’s Giredestrant in ESR1-Mutated, ER-Positive Advanced Breast Cancer
– Filing acceptance based on Phase III data showing giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated... Read more.
Xerox Holdings Corporation Declares Dividend on Common and Preferred Stock
NORWALK, Conn.–(BUSINESS WIRE)–Xerox Holdings Corporation (NASDAQ: XRX) announced today that its board of directors declared a quarterly dividend of... Read more.